Prognostic significance of the C-reactive protein–albumin–lymphocyte (CALLY) index in primary lung malignancies: a systematic review and meta-analysis with GRADE assessment
Preprint
Abstract
Background: The C-reactive protein–albumin–lymphocyte (CALLY) index integrates systemic inflammation, nutritional status, and immune function. We evaluated its association with survival in primary lung malignancies. Methods: Embase, PubMed, Scopus, and Web of Science were searched from inception to 18 September 2026. Risk of bias was assessed using the Quality In Prognosis Studies tool. Hazard ratios (HRs) were synthesized using random-effects models with restricted maximum likelihood estimation and Hartung–Knapp adjustment. Sensitivity analyses, subgroup analyses, and meta-regression examined robustness and heterogeneity. Results: Eleven studies contributed 13 cohorts to the overall survival (OS) analysis and 8 cohorts from seven studies to a combined recurrence/progression-free survival (RFS/PFS) analysis. Lower CALLY was associated with poorer OS (HR 1.78, 95% CI 1.49–2.12; I²=71.6%) and poorer RFS/PFS (HR 1.60, 95% CI 1.40–1.84; I²=0%). Associations persisted in leave-one-out analyses. No statistically significant subgroup differences were detected. Funnel-plot asymmetry suggested small-study effects for OS and RFS/PFS. Seven studies had moderate and four had high overall risk of bias. The certainty of evidence was rated as low for both OS and RFS/PFS, primarily due to risk of bias, heterogeneity, and endpoint indirectness. Conclusion: Lower CALLY was associated with adverse survival outcomes in the current synthesis. Methodological limitations and variation in biomarker measurement and endpoint definitions restrict interpretation. Prospective validation using standardized measurements and clinically coherent outcomes is needed to establish incremental prognostic value and clinical utility.Keywords
This publication has 38 references indexed in Scilit:
- Prognostic Value of the C-Reactive Protein–Albumin–Lymphocyte Index in Hepatobiliary and Pancreatic Cancers: A Systematic Review and Meta-AnalysisJournal of Gastrointestinal Cancer, 2026
- Dynamic Changes in NPAR and the CALLY Score for Predicting Pathological Complete Response in Breast Cancer: A Simple Combined Clinical ScoreClinical Breast Cancer, 2026
- Prognostic Value of Pretreatment C-Reactive–Protein–Albumin–Lymphocyte Index in Colorectal Cancer: Systematic Review and Meta-AnalysisJournal of Gastrointestinal Cancer, 2026
- Prognostic impact of the C-reactive protein–albumin–lymphocyte index in patients with resected lung cancer associated with interstitial pneumoniaSurgery Today, 2026
- Global burden of lung cancer in 2022 and projections to 2050: Incidence and mortality estimates from GLOBOCANCancer Epidemiology, 2024
- The value of CRP-albumin-lymphocyte index (CALLY index) as a prognostic biomarker in patients with non-small cell lung cancerSupportive Care in Cancer, 2023
- Superiority of CRP-albumin-lymphocyte index (CALLY index) as a non-invasive prognostic biomarker after hepatectomy for hepatocellular carcinomaHPB, 2022
- GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risksJournal of Clinical Epidemiology, 2020
- Pretreatment prognostic nutritional index as a prognostic factor in lung cancer: Review and meta-analysisClinica Chimica Acta, 2018
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung CancerJAMA Oncology, 2018